Ritonavir-13C,d3

• UNSPSC Description:

  Ritonavir-13C,d3 is the 13C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

• Target Antigen:

  Apoptosis; HIV; HIV Protease; SARS-CoV

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Apoptosis;Metabolic Enzyme/Protease

• Field of Research:

  Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(C)[C@H](NC(N([13C]([2H])([2H])[2H])CC1=CSC(C(C)C)=N1)=O)C(N[C@H](C[C@H](O)[C@@H](NC(OCC2=CN=CS2)=O)CC3=CC=CC=C3)CC4=CC=CC=C4)=O

• Molecular Weight:

  724.96

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.|[3]Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423-31.|[4]Eagling VA, et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44(2):190-4.|[5]Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57(10):1147-52.|[6]Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9.|[7]Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27(8):902-8.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported